Quilter Investors LTD Invests $4 Million in Amgen, Inc. (AMGN) Stock

Quilter Investors LTD bought a new stake in Amgen, Inc. (NASDAQ:AMGN) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 20,553 shares of the medical research company’s stock, valued at approximately $4,001,000. Amgen comprises 2.7% of Quilter Investors LTD’s investment portfolio, making the stock its 18th biggest position.

A number of other large investors have also recently bought and sold shares of the business. Arlington Partners LLC lifted its holdings in Amgen by 86.7% during the 4th quarter. Arlington Partners LLC now owns 140 shares of the medical research company’s stock worth $27,000 after buying an additional 65 shares in the last quarter. Contravisory Investment Management Inc. purchased a new stake in shares of Amgen in the 4th quarter valued at approximately $50,000. Lavaca Capital LLC purchased a new stake in shares of Amgen in the 4th quarter valued at approximately $78,000. Moody National Bank Trust Division purchased a new stake in shares of Amgen in the 4th quarter valued at approximately $81,000. Finally, Quantamental Technologies LLC purchased a new stake in shares of Amgen in the 4th quarter valued at approximately $131,000. Institutional investors own 81.79% of the company’s stock.

In other news, Director Tyler Jacks sold 20,000 shares of the firm’s stock in a transaction on Thursday, December 6th. The shares were sold at an average price of $195.41, for a total value of $3,908,200.00. Following the completion of the sale, the director now owns 28,979 shares in the company, valued at approximately $5,662,786.39. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Cynthia M. Patton sold 1,777 shares of the firm’s stock in a transaction on Thursday, November 29th. The stock was sold at an average price of $202.88, for a total transaction of $360,517.76. Following the completion of the sale, the senior vice president now owns 23,090 shares of the company’s stock, valued at approximately $4,684,499.20. The disclosure for this sale can be found here. 0.27% of the stock is currently owned by company insiders.

A number of equities research analysts have commented on AMGN shares. Jefferies Financial Group reissued a “buy” rating and issued a $220.00 price objective on shares of Amgen in a research report on Tuesday, December 4th. Morgan Stanley reissued a “buy” rating and issued a $213.00 price objective on shares of Amgen in a research report on Tuesday, December 4th. Goldman Sachs Group reissued a “buy” rating and issued a $232.00 price objective on shares of Amgen in a research report on Tuesday, December 4th. Oppenheimer set a $224.00 price objective on shares of Amgen and gave the company a “buy” rating in a research report on Tuesday, October 30th. Finally, Mizuho reaffirmed a “buy” rating and issued a $206.00 target price on shares of Amgen in a research report on Friday, October 26th. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating and nine have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $205.51.

AMGN stock opened at $186.00 on Monday. Amgen, Inc. has a one year low of $163.31 and a one year high of $210.19. The firm has a market capitalization of $118.52 billion, a PE ratio of 12.92, a PEG ratio of 2.06 and a beta of 1.21. The company has a quick ratio of 2.57, a current ratio of 2.79 and a debt-to-equity ratio of 2.36.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, January 29th. The medical research company reported $3.42 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.26 by $0.16. Amgen had a net margin of 35.35% and a return on equity of 66.74%. The company had revenue of $6.23 billion during the quarter, compared to analysts’ expectations of $5.88 billion. During the same quarter last year, the business earned $2.89 EPS. As a group, research analysts expect that Amgen, Inc. will post 13.93 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, March 8th. Stockholders of record on Friday, February 15th will be paid a $1.45 dividend. This represents a $5.80 annualized dividend and a dividend yield of 3.12%. The ex-dividend date is Thursday, February 14th. This is a boost from Amgen’s previous quarterly dividend of $1.32. Amgen’s dividend payout ratio (DPR) is 36.67%.

ILLEGAL ACTIVITY WARNING: “Quilter Investors LTD Invests $4 Million in Amgen, Inc. (AMGN) Stock” was originally posted by WKRB News and is the sole property of of WKRB News. If you are accessing this story on another domain, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The legal version of this story can be accessed at https://www.wkrb13.com/2019/02/11/quilter-investors-ltd-invests-4-million-in-amgen-inc-amgn-stock.html.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.

Featured Article: What are trading strategies for the 52-week high/low?

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply